The WHO on Tuesday continued to express confidence in the H1N1 (swine flu) vaccine as few mild adverse effects have been reported by patients participating in China’s vaccine campaign, the Associated Press reports. Out of the 39,000 people in China who received the H1N1 vaccine, four reported experiencing side effects such as muscle cramps and headache, according to WHO spokesman Gregory Hartl (Higgins, 10/6).
The number of H1N1 (swine flu) cases reported in WHO regions worldwide has grown by at least 24,000 in two weeks to cross the 340,000 mark since the virus was first detected in mid-April, the CDC reported Monday, according to Agence France-Presse.
U.N. officials on Sunday said that the H1N1 (swine flu) virus had arrived in poorer countries, highlighting a growing need for financial assistance and H1N1 vaccines for such regions, SAPA/News24.com reports.
U.S. health officials announced Thursday the first batches of the H1N1 (swine flu) vaccine the government ordered will begin arriving in designated locations across the country on Tuesday and may be administered in the first patients by the end of next week, Reuters reports.
To Stop HIV Spread,Â Bridge The Divide Between ‘Privileged’ And ‘Forsaken’ Â “With less than half the people who need treatment having access and with each day more people becoming infected with HIV than are started on treatment, we are mortgaging our future. But we are also exposing a fundamental social…
Also In Global Health News: Drought In East Africa; Improving Food Processing In Africa; Hajj Pilgrims Must Take Polio Vaccine; Fighting Insecticide-Resistant Mosquitoes
Oxfam Launches $15M Emergency Appeal For ‘Severe’ East African Drought “A severe and persistent five-year drought” is pushingÂ “[m]ore than 23 million people … towards severe hunger and destitution across East Africa, international aid agency Oxfam has warned as it launches a Â£9.5 million [about $15 million]Â emergency appeal,” the U.K. Press…
Reuters reports on how the results of an experimental AIDS vaccine which showed modest potential for preventing infection are leading researchers back “to the drawing board” as they try to better understand how the AIDS vaccine works.
GlaxoSmithKline (GSK) Chief Executive Andrew Witty on Friday announced Brazil has agreed to buy roughly $2.2 billion of the company’s vaccine for pneumococcal disease, Synflorix, for a period of at least eight years, in exchange for a technology transfer, eventually allowing Brazil to manufacture the vaccine itself, the Wall Street Journal reports.
Additional countries are expected to soon announce they will follow in the footsteps of nine developed countries who recently said they would donate H1N1 (swine flu) vaccine supplies to poorer nations, David Nabarro, of the U.N. said Friday, Reuters reports.
Also In Global Health News: News Outlets Explore AIDS Vaccine Research; Chloroquine Resistance Unraveled; Authorities Contest Maternal Mortality Report
News Outlets Focus On Participants In AIDS Vaccine Study, Potential Impact Of AIDS Vaccine The Associated Press examines the role of the Thai participants in the recent clinical trial of an experimental HIV vaccine which showed modest potential for preventing infection. “Nearly 16,000 Thais ignored the false rumors that they…